11 July 2018 | News
AKYNZEO® was developed by Helsinn, and Glenmark has the exclusive marketing rights for the product in India and Nepal under a licensing agreement with Helsinn
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, announced the launch of AKYNZEO®, a fixed dose combination drug for the prevention of CINV (chemotherapy-induced nausea and vomiting) in the Indian market under an exclusive licensing agreement.
AKYNZEO®, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg, is to be administered in a single capsule that acts on both the two main pathways associated with acute and delayed phases of CINV.
The product has been developed by Helsinn and Glenmark has exclusive marketing rights for AKYNZEO® in India and Nepal.
"Oncology is a key area of focus for Glenmark and we are committed to bringing in new treatment options for Indian patients. Nausea and vomiting associated with chemotherapy has a significant impact on quality of life of cancer patients that can influence a patient's adherence to the treatments being undertaken. AKYNZEO® is a convenient single-dose oral capsule for each chemotherapy cycle that covers both the acute and delayed phase of CINV, avoiding multiple drug antiemetic options and thereby improving patient compliance," said Sujesh Vasudevan, President of India Formulations, Middle East and Africa at Glenmark.